OBJECTIVE: To determine MRI predictors for cognitive outcome in patients with early relapsing-remitting multiple sclerosis (MS). METHODS: Forty-four patients recently diagnosed with clinically definite MS were followed up with clinical and cognitive evaluations at 1, 2, 5, and 7 years and underwent brain MRI including magnetization transfer (MT) imaging at baseline and 2 years. Cognitive evaluation was also performed in 56 matched healthy subjects at baseline. Cognitive testing included the Brief Repeatable Battery. Imaging parameters included lesion load, brain parenchymal fraction (BPF), ventricular fraction (VF), and mean MT ratio (MTR) of lesion and normal-appearing brain tissue (NABT) masks. RESULTS: At baseline, patients presented deficits of memory, attention, and information processing speed (IPS). Over 2 years, all magnetic resonance parameters deteriorated significantly. Over 7 years, Expanded Disability Status Scale score deteriorated significantly. Fifty percent of patients deteriorated on memory cognitive domain and 22.7%of patients on IPS domain. Seven-year change of memory scores was significantly associated with baseline diffuse brain damage (NABT MTR). IPS z score change over 7 years was correlated with baseline global atrophy (BPF), baseline diffuse brain damage, and central brain atrophy (VF) change over 2 years. CONCLUSION: The main predictors of cognitive changes over 7 years are baseline diffuse brain damage and progressive central brain atrophy over the 2 years after MS diagnosis.
OBJECTIVE: To determine MRI predictors for cognitive outcome in patients with early relapsing-remitting multiple sclerosis (MS). METHODS: Forty-four patients recently diagnosed with clinically definite MS were followed up with clinical and cognitive evaluations at 1, 2, 5, and 7 years and underwent brain MRI including magnetization transfer (MT) imaging at baseline and 2 years. Cognitive evaluation was also performed in 56 matched healthy subjects at baseline. Cognitive testing included the Brief Repeatable Battery. Imaging parameters included lesion load, brain parenchymal fraction (BPF), ventricular fraction (VF), and mean MT ratio (MTR) of lesion and normal-appearing brain tissue (NABT) masks. RESULTS: At baseline, patients presented deficits of memory, attention, and information processing speed (IPS). Over 2 years, all magnetic resonance parameters deteriorated significantly. Over 7 years, Expanded Disability Status Scale score deteriorated significantly. Fifty percent of patients deteriorated on memory cognitive domain and 22.7%of patients on IPS domain. Seven-year change of memory scores was significantly associated with baseline diffuse brain damage (NABT MTR). IPS z score change over 7 years was correlated with baseline global atrophy (BPF), baseline diffuse brain damage, and central brain atrophy (VF) change over 2 years. CONCLUSION: The main predictors of cognitive changes over 7 years are baseline diffuse brain damage and progressive central brain atrophy over the 2 years after MS diagnosis.
Authors: N F Kalkers; E Bergers; J A Castelijns; M A van Walderveen; J C Bot; H J Adèr; C H Polman; F Barkhof Journal: Neurology Date: 2001-10-09 Impact factor: 9.910
Authors: R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon Journal: J Neurol Neurosurg Psychiatry Date: 2001-06 Impact factor: 10.154
Authors: C Christodoulou; L B Krupp; Z Liang; W Huang; P Melville; C Roque; W F Scherl; T Morgan; W S MacAllister; L Li; L A Tudorica; X Li; P Roche; R Peyster Journal: Neurology Date: 2003-06-10 Impact factor: 9.910
Authors: Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani Journal: Int J MS Care Date: 2012
Authors: Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier Journal: CNS Drugs Date: 2014-02 Impact factor: 5.749
Authors: Nithin Manchery; Julie D Henry; Andrew Swayne; Reuben Beer; Stefan Blum; Matthew R Nangle Journal: Clin Oral Investig Date: 2021-11-13 Impact factor: 3.573
Authors: James F Sumowski; Maria A Rocca; Victoria M Leavitt; Jelena Dackovic; Sarlota Mesaros; Jelena Drulovic; John DeLuca; Massimo Filippi Journal: Neurology Date: 2014-04-18 Impact factor: 9.910
Authors: Menno M Schoonheim; René M Vigeveno; Fernanda C Rueda Lopes; Petra J W Pouwels; Chris H Polman; Frederik Barkhof; Jeroen J G Geurts Journal: Hum Brain Mapp Date: 2013-08-24 Impact factor: 5.038
Authors: Francesco Patti; Manuela De Stefano; Luigi Lavorgna; Silvia Messina; Clara Grazia Chisari; Domenico Ippolito; Roberta Lanzillo; Veria Vacchiano; Sabrina Realmuto; Paola Valentino; Gabriella Coniglio; Maria Buccafusca; Damiano Paolicelli; Alessandro D'Ambrosio; Patrizia Montella; Vincenzo Brescia Morra; Giovanni Savettieri; Bruno Alfano; Antonio Gallo; Isabella Simone; Rosa Viterbo; Mario Zappia; Simona Bonavita; Gioacchino Tedeschi Journal: PLoS One Date: 2015-03-27 Impact factor: 3.240